SWOT Analysis of Bio-pharmaceutical Industry in Beijing

亚洲社会药学

• Drug Economy • 上一篇下一篇

SWOT Analysis of Bio-pharmaceutical Industry in Beijing

KongYan 1,2, Lian Guiyu 1*

1.School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; 2.China Life Insurance(Group)Company, Beijing 100033, China

出版日期:2016-06-20 发布日期:2016-07-19

SWOT Analysis of Bio-pharmaceutical Industry in Beijing

KongYan 1,2, Lian Guiyu 1*

1.School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; 2.China Life Insurance(Group)Company, Beijing 100033, China

Online:2016-06-20 Published:2016-07-19
Contact: Lian Guiyu, associate professor. Major research area: pharmaceutical science and technology innovation, biological pharmaceutical industry, drug policy, and pharmaceutical enterprise management research. Tel: 13002465888, E-mail: lianguiyu@163.com

摘要/Abstract

摘要： Objective To provide references for Beijing municipal government and biopharmaceutical enterprises to make appropriate development strategies, and to provide references for the development of biopharmaceutical industry in other areas. Methods Literature review and expert consultation were applied. Results and Conclusion A SWOT matrix model for the development of biopharmaceutical industry was established and six strategic measures were put forward according to the result of SWOT analysis of biopharmaceutical industry development in Beijing. Namely, strengthening the government support; making use of Beijing-TianjinHebei collaborative development chance to lift the barriers to industry development; promoting the ability of independent innovation; increasing investment in research and development; expanding investment and financing channels and optimizing the layout of biopharmaceutical industry.

关键词: Beijing, biopharmacy, industry development, SWOT

Abstract: Objective To provide references for Beijing municipal government and biopharmaceutical enterprises to make appropriate development strategies, and to provide references for the development of biopharmaceutical industry in other areas. Methods Literature review and expert consultation were applied. Results and Conclusion A SWOT matrix model for the development of biopharmaceutical industry was established and six strategic measures were put forward according to the result of SWOT analysis of biopharmaceutical industry development in Beijing. Namely, strengthening the government support; making use of Beijing-TianjinHebei collaborative development chance to lift the barriers to industry development; promoting the ability of independent innovation; increasing investment in research and development; expanding investment and financing channels and optimizing the layout of biopharmaceutical industry.

Key words: Beijing, biopharmacy, industry development, SWOT

. SWOT Analysis of Bio-pharmaceutical Industry in Beijing[J]. 亚洲社会药学.

[1]	Wang Mingzheng, Wang Shuling. Suggestions on the Good Development of Pharmaceutical Cold Chain Logistics in China [J]. 亚洲社会药学, 2024, 19(3): 263-271.
[2]	Xiu Yu, Wang Shuling. Investigation and Countermeasures of the Development of Chinese Pharmaceutical E-commerce in the B2C Model Based on PEST-SWOT Analysis[J]. 亚洲社会药学, 2023, 18(4): 398-405.
[3]	Wang Shuling, Shi Ping. Analysis on the Development Dilemma and Opportunity of Independent Clinical Laboratory Based on PEST-SWOT[J]. 亚洲社会药学, 2021, 16(1): 31-40.
[4]	Liu Tianchi, Zeng Yu. SWOT Analysis and Countermeasures Study on TCM Industry in Hainan Free Trade Port[J]. 亚洲社会药学, 2021, 16(1): 41-47.
[5]	Lv Xin, Chen Yuwen. SWOT Analysis of ARNI Anti-Heart Failure Drugs in Chinese Market[J]. 亚洲社会药学, 2020, 15(3): 139-144.
[6]	Fu Geyang, Tian Lijuan. The Analysis of Marketing Strategy of Plendil[J]. 亚洲社会药学, 2020, 15(1): 37-43.
[7]	De Xianhui, An Lianyu, Wang Shuling. Development of Licensed Pharmacists in China: Dilemma and Opportunity[J]. 亚洲社会药学, 2019, 14(4): 192-203.
[8]	Shi Ping, Wang Shuling. Pharmaceutical WeChat Public Platform Based on PEST-SWOT Matrix Model: Current Status and Development Strategies [J]. 亚洲社会药学, 2019, 14(4): 209-218.
[9]	Fu Yang, Tian Lijuan. SWOT Analysis and Development Suggestions on HK Drugs of G Pharmaceutical Firm[J]. 亚洲社会药学, 2019, 14(2): 55-58.
[10]	Xu kai, Sun Lihua. Biopharmaceutical Industrial Zone in the United States: Development Experience and Its Enlightenment[J]. 亚洲社会药学, 2019, 14(1): 1-6.
[11]	Ding Ling, Dong Li. CRO in China: SWOT Analysis and Development Strategies[J]. 亚洲社会药学, 2018, 13(3): 80-85.
[12]	Wang Tao, Wu Zhi’ang, Li Shuchuen. Application of SWOT Analysis and Porter’s Five Forces Analysis to State-owned Enterprise Affiliated Hospitals in China [J]. 亚洲社会药学, 2017, 12(2): 41-49.
[13]	HAN Xue-ting;HUANG Zhe. Study on O2O Pharmacy E-commerce Based on SWOT Analysis[J]. , 2015, 10(2): 97-101.
[14]	BAI Jian;;DAI Juan;LI Ye. Diagnostic Reagent Industry in China: SWOT Analysisand Countermeasures[J]. , 2014, 9(3): 119-123.
[15]	楊敏;李野;付非;閆雙雙. 中國心血管系統藥物市場現狀及企業未來發展戰略研究[J]. , 2011, 6(2): 96-99.

亚洲社会药学

SWOT Analysis of Bio-pharmaceutical Industry in Beijing

SWOT Analysis of Bio-pharmaceutical Industry in Beijing

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价